Moderna, Inc.

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
60770K107
SEDOL
BGSXTS3
CIK
0001682852
www.modernatx.com
LEI:
©
Moderna is a Member of Themefolio
          Covid19-STX          
FIGI: BBG003PHHZT1
MRNA
Moderna, Inc.
GICS: - · Sektor: Healthcare · Sub-Sektor: Biotechnology
AI
PROFILER
NAME
Moderna, Inc.
ISIN
US60770K1079
TICKER
MRNA
MIC
XNAS
REUTERS
MRNA.OQ
BLOOMBERG
MRNA US
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
GIF DE 728x90
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants
TradingView ActivTrader MT4 MT5
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von ACCESSWIRE bereitgestellt.
Mo., 25.11.2024       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:7th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 4th at 1:20pm ETPiper Sandler 36th Annual Healthcare Conference, on Thursday, December 5th at 10:30am ETA live webcast of...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Di., 12.11.2024       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation."We are honored to be recognized by BioSpace as the most desirable large employer in the life scien...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Fr., 08.11.2024       Moderna
US60770K1079

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringesCanada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and QatarCAMBRIDGE, MA / ACCESSWIRE / November 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced Health Canad...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Do., 07.11.2024       Moderna
US60770K1079

Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billionInitiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenzaAnnou...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Do., 31.10.2024       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESSWIRE / October 31, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:Guggenheim's Inaugural Healthcare Innovation Conference, on Tuesday, November 12th at 10:00am ETUBS Global Healthcare Conference, on Wednesday, November 13th at 3:30pm PTJefferies London Healt...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Do., 24.10.2024       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2024 Top Employers Survey for the tenth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with res...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Do., 17.10.2024       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Present...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Mi., 02.10.2024       Moderna
US60770K1079

Hussain brings more than 35 years of commercial leadership and operating experience in healthcare, most recently serving as CEO of Vifor PharmaAs former Global President of GSK, Pharmaceuticals and Vaccines, Hussain brings significant global vaccine commercialization experience in emerging and mature markets, along with significant Board of Directo...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Mo., 30.09.2024       Moderna
US60770K1079

CAMBRIDGE, MA and TAIPEI, TAIWAN / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Cenra Healthcare, the sales and marketing arm of Cenra Inc., today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Taiwan, including Moderna's COVID-19 va...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Mo., 30.09.2024       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403. Global recruitment for the Nova...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S